A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against ...

Investing.com -- Smid-cap biotech stocks are poised for a stronger 2026 as the sector emerges from what UBS describes as a “cyclical trough” driven by pricing pressure, FDA uncertainty, capital ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

The New Year's Champagne turned flat for Madrigal Pharmaceuticals ( MDGL 5.01%) on Tuesday. Investors traded out of the ...

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro Stoxx 50 Index and smaller names including Valneva SE and Inventiva also ...

Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...